Literature DB >> 19148480

Different intracellular compartmentalization of TA and DeltaNp73 in non-small cell lung cancer.

Angela Di Vinci1, Fausto Sessa, Ida Casciano, Barbara Banelli, Francesca Franzi, Claudio Brigati, Giorgio Allemanni, Patrizia Russo, Lorenzo Dominioni, Massimo Romani.   

Abstract

The p53 homologue p73 is overexpressed in many tumors, including lung cancer. We have evaluated the differential expression and subcellular localization of the functionally distinct apoptotic (TA) and anti-apoptotic (DeltaN) isoforms of p73 in non-small cell lung cancer (NSCLC), their possible association with p53 expression and determined the methylation status of the two p73 gene promoters (P1 and P2) in this tumor type. Immunohistochemical analysis showed that both isoforms are expressed in the majority of cases. However, the oncogenic DeltaN variant, derived from the transcripts DeltaN'p73 (from P1) and/or DeltaNp73 (from P2), is localized mainly in the nucleus, while the anti-oncogenic TAp73 isoform (derived from a P1 transcript) is sequestered in the cytoplasm in almost all cases analyzed. Significant correlation was found between p53 and DeltaNp73 expression (p=0.041). Methylation analysis conducted on 41 tumor samples showed that the P1 promoter is almost invariably unmethylated (39/41 cases) whereas P2 was found completely methylated in 17 cases and partially or totally unmethylated in 24 samples. No correlation was found between the methylation status of P1 and P2 and p73 expression. Our results demonstrate that both isoforms contribute to p73 overexpression in NSCLC and suggest that their different intracellular localization may reflect an alteration of the functional p53-p73 network that might contribute to lung cancer development.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19148480

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  7 in total

1.  Overexpression of the ∆Np73 isoform is associated with centrosome amplification in brain tumor cell lines.

Authors:  Erika Mikulenkova; Jakub Neradil; Karel Zitterbart; Jaroslav Sterba; Renata Veselska
Journal:  Tumour Biol       Date:  2015-04-25

Review 2.  A balancing act: orchestrating amino-truncated and full-length p73 variants as decisive factors in cancer progression.

Authors:  D Engelmann; C Meier; V Alla; B M Pützer
Journal:  Oncogene       Date:  2014-11-10       Impact factor: 9.867

3.  Analysis of the intracellular localization of p73 N-terminal protein isoforms TAp73 and ∆Np73 in medulloblastoma cell lines.

Authors:  Marta Nekulová; Karel Zitterbart; Jaroslav Sterba; Renata Veselská
Journal:  J Mol Histol       Date:  2010-08-28       Impact factor: 2.611

4.  Quercetin abrogates chemoresistance in melanoma cells by modulating deltaNp73.

Authors:  Thilakavathy Thangasamy; Sivanandane Sittadjody; Geoffrey C Mitchell; Erin E Mendoza; Vijayababu M Radhakrishnan; Kirsten H Limesand; Randy Burd
Journal:  BMC Cancer       Date:  2010-06-11       Impact factor: 4.430

Review 5.  Mechanisms, function and clinical applications of DNp73.

Authors:  Cuixia Di; Lina Yang; Hong Zhang; Xiaofei Ma; Xin Zhang; Chao Sun; Hongyan Li; Shuai Xu; Lizhe An; Xun Li; Zhongtian Bai
Journal:  Cell Cycle       Date:  2013-06-13       Impact factor: 4.534

6.  p53 Family: Role of Protein Isoforms in Human Cancer.

Authors:  Jinxiong Wei; Elena Zaika; Alexander Zaika
Journal:  J Nucleic Acids       Date:  2011-10-09

7.  A novel dual signaling axis for NSP 5a3a induced apoptosis in head and neck carcinoma.

Authors:  Luca D'Agostino; Antonio Giordano
Journal:  Oncotarget       Date:  2011-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.